Scholarly article on Androst-16-en-3-one 32925-78-3 from Journal of Agricultural and Food Chemistry p. 1241,1242,1243

DOI: 10.1021/jf60214a033

Source and publish data:

Journal of Agricultural and Food Chemistry p. 1241,1242,1243 (1977)

Update date:2022-08-05

Topics:

Authors:

Thompson

Pearson Pearson

Read Full Text PDF DownLoad Join now for total 90,000,000 free articles

Article abstract of DOI:10.1021/jf60214a033

Full text of DOI:10.1021/jf60214a033

Products guided by the article

Product name:Androst-16-en-3-one

Cas No:32925-78-3

R&D Labs maybe for 32925-78-3

Shanghai Hanhong Scientific Co.,Ltd.

website:http://www.chemvia.com

Contact:+86-21-64541543,54280654,13918533501

Address:Jiachuan Road 245
Lanzhou huibang biological chemical technology Co., LTD

Contact:0931-7843964

Address:NO.2011,Yannan Road,Chengguan,
Jiangsu Mingchem Corporation

website:http://www.mingchem.com/en/index

Contact:0519-85170101-802

Address:Fifth Floor,B of Beihua Buliding,520 Road of Science and Education City,Changwu middle road NO.801,Wujin District,Changzhou,Jiangsu province
Phantom-pharma

Contact:

Address:
Suzhou CarbonWell Pharma-Tech Co., Ltd

Contact:Tel: + 86 (0)512-8898-1216; + 86-18606258602

Address:2358 Changan Road, Wujiang Scientific Innovation Park, Wujiang, Jiangsu Province, P. R. China 215200

Relevant to this article

Doi:10.1007/BF00567852
()
Synthesis and anticancer activity of novel rapamycin C-28 containing triazole moiety compounds

Doi:10.1002/ardp.201800123
(2018)
Synthesis of a Tri-, a Penta-, and a Hepta-saccharide Containing Terminal N-Acetyl-β-D-lactosaminyl Residues, Part of the 'Complex-type' Carbohydrate Moiety of Glycoproteins

Doi:10.1039/P19810002070
(1981)
Independent generation and characterization of a C2′-oxidized abasic site in chemically synthesized oligonucleotides

Doi:10.1021/jo049033d
(2004)
Thermolysis of dimethyl 3,3-(2,2′-biphenylyl)-3H-pyrazole-4,5-dicarboxylate

Doi:10.1021/jo00322a042
(1981)
Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation.

Doi:10.1021/jm049752k
(2004)

Article Doi

DOI: 10.1021/jf60214a033